Мониторинг в терапии хронического миелолейкоза иматинибом

Sergey Ivanovich Kutsev, О. С. Оксенюк · Клиническая онкогематология. Фундаментальные исследования и клиническая практика · 2009

International IRIS study has shown the high effectiveness of imatinib in chronic myeloid leukemia (CML) therapy. The failure of imatinib therapy or loss of the achieved response has been associated with heterogeneous BCR-ABL related or nonrelated mechanisms of resistance to imatinib. The achievement of cytogenetic and molecular response to imatinib therapy may relate to the blood level of imatinib. In this review the role of therapeutic drug monitoring of imatinib in the optimization of CML therapy was discussed.

Cited by 0 works.

Authors